Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

November 3, 2021

NASDAQ US Health Care Biotechnology earnings 46 min

Earnings Call Speaker Segments

Holly Manning

executive
#1

Operator, thank you. Good day, everyone, and welcome to the Agios conference call for the third quarter of 2021. You can find the slides for today's call in the Investors section of our website, agios.com. With me today to give prepared remarks are our Chief Executive Officer, Dr. Jackie Fouse; our Chief Medical Officer, Dr. Sarah Gheuens; our Chief Commercial Officer, Darrin Miles; our Chief Financial Officer and Head of Legal and Corporate Affairs, Jonathan Biller; and our Chief Scientific Officer, Dr. Bruce Car, who will be joining us for Q&A. Before we get started, I'd like to remind everyone that some of the statements we make on this call will include forward-looking statements. A range of dangers, unknowns, and additional elements might cause what actually happens and what we achieve to be substantially different from anything suggested or stated as forward-looking. These include the ones described in the documents we most recently submitted to the SEC, along with any subsequent submissions we might file with that agency. Having said that, I'll now hand things over to Jackie.

Jacqualyn Fouse

executive
#2

Thank you, Holly. Hello, everyone, and I appreciate you being with us for our third quarter 2021 results call. At Agios, we kept up strong execution on both the clinical and operational fronts; our NDA and MAA filings remain on schedule, and our commercial team is concentrating on getting ready to launch mitapivat, which could become the first disease-modifying therapy available for pyruvate kinase deficiency. The infrastructure for supporting patients is ready. Our field team, made up of sales representatives and nurse clinical educators, is fully engaged with health care providers, and our efforts to educate people about the disease keep gaining momentum. Alongside mitapivat, we're putting significant effort into getting three key trials up and running — one apiece in thalassemia and sickle cell disease — with the goal of kicking all of them off before 2021 wraps up. What these studies make clear is that mitapivat has the potential to function like an entire pipeline contained within one therapy, and to emerge as a meaningful new option for patients dealing with these deeply difficult, historically neglected lifelong hemolytic anemias. Beyond mitapivat, we continue to move our earlier-stage clinical and R&D programs forward, aiming to establish durable growth potential for the future that's grounded in our leadership in PK activation and cellular metabolism — all of it staying within our central emphasis on diseases with a genetic basis. There's a lot of enthusiasm on our end for this year's American Society of Hematology Annual Meeting. At that event, fresh findings from across our clinical programs will be shared, among them significant new information regarding sickle cell disease, thalassemia and PK deficiency. Come November 17, we intend to hold an Investor Day, where we'll offer encouraging news about the research and development pipeline, along with deeper detail on how we plan to commercialize mitapivat for PK deficiency and what we anticipate there. Looking ahead to the close of this year and into 2022, Agios finds itself in a very strong position to begin its next stage of expansion, with the upcoming commercial debut of our first genetically defined disease therapy, three pivotal studies in adults, two pivotal pediatric trials in PK deficiency, and a deep pipeline full of options and promise; having said that, I'll hand things over to Sarah now so she can take us through our clinical development programs in greater depth. Sarah, congratulations on joining your first quarterly results call as Agios' CMO.

Sarah Gheuens

executive
#3

Appreciate that, Jackie. What excites us deeply is the potential to transform the lives of patients whose diseases have a genetic cause — beginning with mitapivat for PK deficiency, as well as other hemolytic anemias that represent a major unmet medical need. During Q3, as I'll describe, momentum continued across all of our clinical programs; on the PK efficiency front, we remain engaged with regulators in both the U.S. and EU as they review our regulatory submissions for mitapivat. That constructive dialogue gives us encouragement, and as part of the review process, we are currently responding to inquiries from regulators in both the U.S. and EU. The FDA granted priority review to our new drug application, so the February 17 PDUFA date remains unchanged. Based on the interactions we've had up to now, we aren't expecting an advisory committee meeting at this stage. In the EU, following the standard procedure, we received questions from the rapporteur along with the critical assessment prepared by the co-rapporteur. For our marketing authorization submission, we remain on schedule, with a possible green light anticipated during the latter half of 2022. The filings contain results from the Phase III ACTIVATE and ACTIVATE-T trials involving adults with PK deficiency who receive either nonregular or regular transfusions. Both trials achieved their primary endpoints, along with key secondary endpoints and patient-reported outcomes, and are bolstered by supportive findings from the two extension studies currently underway. This body of data highlights how mitapivat could become the first treatment option for PK deficiency patients across the entire disease spectrum. We plan to present longer-term extension findings in PK deficiency at ASH this December, and we're eager for the ASH abstracts to become available online tomorrow. Additionally, the pediatric clinical trial for PK deficiency is still expected to begin during 2022. Turning to thalassemia, we have started both of our worldwide placebo-controlled pivotal studies of mitapivat, known as ENERGIZE and ENERGIZE-T. The first site has completed its site < >, and we anticipate enrolling the initial patient shortly. As a reminder, ENERGIZE will study 171 patients who are randomly assigned in a 2:1 ratio to receive either 100 milligrams of mitapivat twice per day or placebo, among individuals with alpha and beta thalassemia who do not receive regular transfusions. The main goal is hemoglobin response, which is defined as an increase of at least 1 gram per deciliter in the average hemoglobin concentration from week 12 through week 24 relative to baseline. In ENERGIZE-T, we plan to enroll 240 patients and assign them in a 2:1 ratio, with one group receiving 100 milligrams of mitapivat twice a day and the other receiving placebo. Participants will include individuals with alpha thalassemia as well as beta thalassemia who need regular transfusions, which we define as having received 6 to 20 red blood cell units during the 24 weeks before randomization. For the main goal, we are looking at transfusion reduction response—meaning a drop of at least 50% in transfused blood cell units, along with a decrease of 2 or more units of transfused red blood cells, during any consecutive 12-week stretch up to week 48, measured against baseline. We are excited to advance these studies and believe mitapivat may offer a valuable treatment choice for patients living with alpha or beta thalassemia. During ASH, we intend to share data from a longer-term extension study involving alpha and beta thalassemia patients who are not regularly transfused and who completed the Phase II core period. On the sickle cell disease front, we remain on track to begin our pivotal Phase II/III trial before this year ends. Jackie noted earlier that we just unveiled the program's name: RISE-UP. This name was developed together with a worldwide group of sickle cell advocates, and it holds deep meaning for that community. We were delighted to introduce it for the first time at last month's Sickle Cell Disease Association of America Convention, and the enthusiastic feedback we've received has been extremely rewarding. For this Phase II/III trial, we're going to be enrolling people who are 60 years of age or older, and those individuals need to have had a minimum of 2 and a maximum of 10 sickle cell pain crises during the preceding 12 months. Also required is a hemoglobin level at screening that sits somewhere between 5.5 and 10.5 grams per deciliter. Within the Phase II part of RISE UP, a total of 69 patients are going to be assigned randomly in a 1:1:1 ratio, receiving either 50 mg of mitapivat given twice a day, 100 mg of mitapivat given twice a day, or a placebo that's matched. When it comes to the primary endpoints, one is hemoglobin response, and we define that as an improvement of at least 1 gram per deciliter in the average hemoglobin concentration when comparing week 10 through week 12 against baseline. The other primary endpoint involves the kinds of adverse events that occur. What we learn from these data should allow us to set a clear dosing approach for the Phase III portion. Once we've analyzed the Phase II data, we'll move into the Phase III part of RISE UP. In that stage, 198 patients get randomized in a 2:1 ratio, receiving either the Phase II dose that was selected or a matching placebo. Two primary endpoints are being used here. The first is hemoglobin response, which means an average hemoglobin rise of at least 1 gram per deciliter between baseline and week 52. The second is the yearly rate at which sickle cell pain crises occur. Our view is that this combined Phase II/III approach reduces the risk to the approval pathway for mitapivat in a disease that presents real challenges, while also raising the odds of securing a label with a broad indication. In addition, we're still partnering with the NIH and University of Utrecht on their sickle disease research involving mitapivat. Findings from both trials should be shared at ASH. At the NIH, Dr. Thein has 17 patients in the core study and continues to enroll participants in the extension phase. We expect the ASH data sets to provide further efficacy, safety, and translational information that bolsters the clinical development of mitapivat for individuals with sickle cells. Building on what we've learned as pioneers in PK activation, we're moving forward with AG-946, our new PK activator. Right now it's in a Phase I trial that starts with healthy volunteers and then moves into a sickle cell disease portion, which we're aiming to kick off in 2022. Data from the healthy volunteer part of that Phase I study will be presented at ASH. Like Jackie mentioned, we're planning to take a closer look at our R&D pipeline at the investor event coming up on November 17. With that, I'll turn it over to Darrin, our Chief Commercial Officer.

Darrin Miles

executive
#4

Thank you, Sarah. We have roughly 4 months remaining until our product in the U.S. gets approved and launched, and I feel quite good about where we stand on pre-approval disease education, matching patients with physicians, and getting everything ready for launch overall. Q3 marked the first time we had all of our customer-facing teams fully staffed, covering sales representatives, clinical nurse educators, and patient support managers. We increased both in-person and digital efforts around disease education, which included live programming to educate health care providers as well as seminars focused on patients. During the quarter, we sped up the profiling and validation of physicians and patients, and we keep trimming our list of targeted physicians down to what we expect will come to roughly 2,600 doctors. While doing this profiling, our field team verified findings from our latest quantitative market research: the physicians we're targeting right now are actively treating 3 to 5 hemolytic anemia patients whose etiology is unknown, and most of those individuals probably qualify for genetic testing through Anemia ID so that a definitive diagnosis can be reached for their hemolytic anemia, which could potentially include PK deficiency. Looking at the profiles of those physicians confirmed to be treating PK deficiency at present, a large number have 1 to 2 patients with a confirmed PK deficiency diagnosis who are being managed. On top of that, with the new ICD-10 code for PK deficiency having recently been approved, we anticipate being able to sharpen our targeting even further to locate patients who were diagnosed with PK deficiency previously. Our sales team, which we call hemolytic anemia specialists, along with clinical nurse educators, are likewise teaching practices about how anemia ID is available and responding to inquiries regarding the service; during the third quarter, we saw the biggest quarter-over-quarter rise in requests for anemia ID kits since this program first launched in December. That shows both how much our educational work is having an effect and how eager the community is to figure out what's behind their patient's hemolytic anemia, which may involve PK deficiency. Over the next several months, we plan to grow this service by helping patients get direct access to genetic counselors, who can offer them further assistance. Our belief is that this will enable even more patients who want to start the testing process by themselves and, once diagnosed, handle their disease better. After a patient's PK deficiency diagnosis is confirmed, our hemolytic anemia specialist team teaches practices about disease education and the other support available through myAgios, our patient-assisted service. The team urges practices to let diagnosed patients know about the service, and from there we can move forward with the enrollment process. This positions Agios as well as possible to customize support for patients diagnosed with PK deficiency and link them to the wider PK deficiency community. We have also kept up our engagement with payers throughout the quarter, teaching them about the natural history and burden of the disease, such as morbidities and complications across the spectrum of PK deficiency patients no matter their transfusion history, along with a summary of the Phase III data; through that process, we gained a better understanding of their most urgent questions and what they anticipate from Agios when potential approval occurs. It's understood that getting a novel therapy covered by formularies requires a period of time prior to achieving the best possible access, particularly during the initial 9 to 12 months following approval, since payers assemble P&T committees on staggered timelines. Such conversations also assist us in crafting approaches that help payers while they establish coverage rules. On the whole, momentum keeps building as we approach the anticipated 2022 approval, with every week setting a fresh benchmark for physician and patient profiling and education, alongside consistent advancement toward launch readiness. I'm eager to go through specifics regarding commercial strategy, such as our headway on patient profiling, distribution, and additional topics, at Investor Day in November. Having said that, I'll pass things along to Jonathan for a look at third quarter financials. Jonathan?

Jonathan Biller

executive
#5

Appreciate that, Darrin. You can find our Q3 2021 financial results in the press release that went out this morning, and I'll walk through the highlights. Additional detail will come in our 10-Q filing later today. Just as a reminder, when we discuss third quarter financial results, we're only covering continuing operations on a comparative basis, so the divested oncology business is not included. R&D expenses came to $64 million in the third quarter, roughly $12 million higher than the third quarter of 2020. That year-over-year rise in R&D was mainly attributable to start-up costs tied to the Phase III studies of mitapivat in thalassemia and sickle cell disease, along with our disease education and engagement work for mitapivat and PK deficiency, thalassemia and sickle cell disease. SG&A expenses totaled $27.2 million in the third quarter, versus $28.3 million in the third quarter of 2020. We additionally recorded $2 million of TIBSOVO royalty income during the third quarter of 2021, which sits within the gain on sale of oncology business line item on our income statement. We closed out the quarter with roughly $1.4 billion in cash, cash equivalents and marketable securities. Given that cash balance, we believe we can fund our current operating plan through major catalysts to cash flow positivity without raising additional equity. During Q3, we bought back about 5.3 million shares for $254 million, which works out to an average price per share of $47.94. From when we began repurchasing shares through the third quarter, we've completed approximately $783 million, or just under 2/3 of the $1.2 billion authorization from our Board of Directors. The face of our 10-Q also captures repurchases from September 30 up to the Q's filing date, and it shows a year-to-date share count reduction of more than 16 million shares, or just over 23% of where we started, with total spend of just over $800 million. Because of the substantial progress achieved in the first 6 months of our repurchase program, plus the alternative investment opportunities we're seeing, we've paused share repurchases. This approach lets us direct additional capital toward accelerating pipeline programs and/or complementary business development opportunities that may come up; we retain the optionality to buy back shares under our remaining authorization. As Jackie and Sarah said at our Investor Day on November 17, we're looking forward to updating investors on our internal pipeline progress and some new investment opportunities we see with our internally discovered drugs. With that, operator, please open the line for questions.

John Newman

analyst
#6

My question concerns the Phase III trial of mitapivat for sickle cell disease. First, I'd like to know whether the endpoints are co-primary. Second, for that Phase III study, do you intend to enroll patients who had a minimum number of pain crises at baseline?

Sarah Gheuens

executive
#7

I appreciate the question. This is Sarah, the new CMO. Regarding your first question about the Phase III and its endpoints: there are 2 distinct primary endpoints. That design is quite intentional, using an alpha split across 2 primary endpoints, which lets us proceed to testing of secondary endpoints should we achieve 1 or both of the primary endpoints. Those endpoints consist of hemoglobin response and an analyzed rate of sickle cell pain crises. As for your second question, yes — within our inclusion criteria, patients are required to have experienced at least 2 and as many as 10 pain crises during the year before enrollment.

Alethia Young

analyst
#8

I wanted to ask about the sickle cell pivotal study, if that's alright. Do you permit hydroxyurea to be used alongside, and do you expect it would pair effectively with mitapivat?

Sarah Gheuens

executive
#9

Absolutely, yes. Hydroxyurea is in fact permitted in the trial. We've actually produced data from sickle cell disease patients who were on hydroxyurea during exposure to mitapivat. Our approach for handling that is to stratify by hydroxyurea within the clinical trial.

Alethia Young

analyst
#10

when it comes to hydroxyurea, compared with patients who weren't on it, did you notice any variation in effect?

Sarah Gheuens

executive
#11

could you repeat that?

Alethia Young

analyst
#12

When mitapivat was used alongside something else, does that change anything compared with when it wasn't?

Sarah Gheuens

executive
#13

Not at all. Plus it's still too soon to know, isn't that right? So that's a thing we'd want to examine through a subgroup analysis once Phase III wraps up.

Kennen MacKay

analyst
#14

Could you share your latest perspective on how often pyruvate kinase deficiency occurs and how many people have it, drawing on the patient monitoring and identification work you've been doing through the PK deficiency natural history study or your Peak Registry? And perhaps for Darrin, since launch is getting nearer and these efforts are ramping up, I'm curious whether those prevalence figures have shifted or developed in any way as time has passed.

Darrin Miles

executive
#15

Sure. This is Darrin. The — it's still early, correct? So the — our guidance has been a prevalence figure of 3,000 to 8,000 across the U.S. and the 5 EU; so figure roughly $1,500 to $4,000 within the U.S. The — obviously we remain in the early stages of locating patients, and we recognize that this will keep expanding as we head toward launch, which ought to speed up even more once approval comes through; so at present, for planning purposes, we remain inside that range. Our assumption is that we're at approximately 3,000, and that's the figure our planning is built around. But we should be able to verify that going forward. One thing that will help going forward is uptake of the newly approved ICD-10 code for PK deficiency. But that only received approval recently. And so some time will pass before we observe it being used across the board by the community.

Anupam Rama

analyst
#16

From what I understand, the AG-946 healthy < > data came out at ASH, and I believe there was an optional sickle cell cohort in that trial. Today's slides also laid out some additional indications. So what comes next for this program? And might we get a clearer picture of that at R&D Day in a couple of weeks?

Sarah Gheuens

executive
#17

Yes, so you will definitely be hearing more about the AG-946 development programs at the Investor Day on November 17. At this point, it is in the healthy volunteer portion, with a second part of the clinical trial centered on sickle cell disease; we're excited about that, since it will let us generate data in the setting of hemolytic anemias. And from there, we have a great deal of optionality. So we look forward to discussing more with you on November 17.

Marc Frahm

analyst
#18

Maybe I could just ask a quick follow-up about the patient prevalence work Darrin has been doing. Could you share some sense of what the anemia ID test results look like? Are they coming in similar to what was seen in Spain? In the very early days, I believe you said they were, but it was early on, so I'm interested whether that pattern is holding up. And then, when you say the demand volumes for those tests rose the most quarter over quarter in Q3, could you put a number on that compared with the first half? Did Q3 bring as many tests as the entire first half, or was it less, or more?

Darrin Miles

executive
#19

That's several questions in one, but it's a fair one. Okay, so, packet. As I said during my prepared remarks, requests for the test rose very sharply in Q3. Much of that ties to growing momentum at Agios, and it's also the first complete quarter with our field team in place, correct? They've been out educating the practices, and then the practices — and patients will choose to order the test. So by the close of Q3, we're just under roughly 2,000 tests. As for the results we're observing, I anticipated fluctuation, right, especially since the volume of test results requested — the additional tests get run and then results get reported. And there's a meaningful — there's a substantial gap between the setting where the Spanish study took place, a controlled study setting, and the all-comer type of experience we have in the U.S., plus in the U.S. the test lets physicians examine a whole host of possible explanations for a patient's hemolytic anemias. So in Spain, we observed roughly 20%. We thought it would come in lower, but we think we know precisely what that figure would be; so I'd say 20% remains the top of the range. I think it would be misleading to tell you precisely where things stand today, because I'd love to see this adopted further and more uniformly across the country. We have some very strong pockets of utilization, but I want to see it used more widely. And I want more confirmed tests coming through before we begin routinely reporting what we're seeing there.

Michael King

analyst
#20

Nice work on the momentum. My market questions have probably been covered by plenty of folks already. So maybe I'll pivot to reimbursement, Darrin, could you — Perhaps share what you anticipate regarding the share of patients you believe will be covered through private pay versus Medicare or Medicaid? And which criteria will be necessary for you all to secure the reimbursement you'd anticipate for mitapivat in PKD?

Darrin Miles

executive
#21

Sure, sure. No, I've devoted all this effort toward being ready to deliver that information to you at the Investor Day later this month, but here's a preview; so our expectation is that it's — that the — what we'll see for PKD mirrors what we would see across the overall U.S. population. So roughly 55% or so of patients, we anticipate 55% to 60% ought to be commercial, almost an even split 15% or so, Medicare, 50% Medicaid and then the remainder a number of other < > and cash. What we can anticipate is that there's going to be a ramp right so you will have full formulary coverage for patients, especially commercial patients. That will, to a great extent, hinge on when commercial payers are going to hold their P&T committee meetings, which fall on the ID sets right? So reaching universal coverage there will require time. Medicaid and Medicare typically trail so that might be somewhat slower than commercial. Regarding what payers require from us. I think the point that's been quite evident. And by this stage now, we've had a multitude of one-on-one conversations with individual payers and a decent amount of research on this by now. If we succeed in making — in establishing a solid grasp of the natural history of the disease the long-term morbidities and complications tied to PKD, then the unmet need, the severity of the disease, irrespective of transfusion history is fairly well accepted and understood by the community, right? Once we build that story. And so then — and the clinical data, right? So the safety efficacy data are quite clear and compelling. So there's a bit of persuading you have to do there. You just have to ensure people possess a solid grasp of it. Once that's in place, then we anticipate fairly favorable access which you'll see differences depending on individual patients < > benefit designs. But we would anticipate pretty good access. The crux will boil down to how the label looks at the end of the day and what price we select, right, to ensure that we're sort of optimizing the business opportunity but ensuring that we're also optimizing the ability for all patients to be able to access the treatment as their physician warrants is appropriate.

Michael King

analyst
#22

Let me just squeeze in one more quick question, if I can. When it comes to genetic testing versus actually getting patients started on mitapivat therapy, are you expecting one single point of contact? Because what would really bother me is if there's confusion — whether it's around getting the genetic test or around handing things off to a physician who then writes the prescription for that patient. How will that whole process be handled?

Darrin Miles

executive
#23

Sure. So PerkinElmer is the partner we've teamed up with to deliver the genetic test. That said, not every single patient will necessarily undergo genetic testing. The test that tends to be used most often is the enzyme assay. Genetic testing does add value and can serve as confirmation in that setting. So people aren't restricted to the tool that we back. What we're planning to put in place is a mandated hub. That means each time a script is written, the physician sends it to myAgios, which is our patient support service, and from there patients choose to opt in to the service. That then opens the door for us to make sure the right confirmation of the patient's diagnosis is on file, to help them with their interactions with payers, and to work with both the patients and the practices on all the right disease education, put them in touch with other patients in the PKD community, that kind of thing, and offer wrap-around support around adherence for the patient too. So going back to your question — physicians aren't restricted only to the genetic tests that we offer. But through the prescription and fulfillment process, we can deliver a seamless service that makes sure the patient successfully gets onto treatment. And it gives us the best visibility into individual patients.

Mark Breidenbach

analyst
#24

Likely this piggybacks on what Anupam asked before; it's likely aimed at Sarah about AG-946. I'm curious what sort of elements drive the choice to initially place 946 into a sickle cell cohort rather than certain other hemolytic anemias? And I also wonder whether you're observing any pharmacodynamic thresholds that 946 must get past in healthy volunteers to warrant ongoing development when it comes to 2, 3-DPG reduction and perhaps ATP increases, that kind of thing. What might you view as an optimal case coming from the healthy volunteer data?

Sarah Gheuens

executive
#25

Okay. Great. So the present protocol, how it's constructed, produces — it's a really standard single ascending dose, multiple ascending dose trial in healthy volunteers; and we are, naturally, seeking pharmacodynamic engagement among that group and aiming to max out and additionally produce suitable safety data, which is quite classic Phase I style work. And the protocol is then constructed with particular choices tied to the pharmacodynamic engagement seen in healthy volunteers to advance with the correct doses in the 946 sickle cell disease portion of the study. As for why sickle cell, the sickle cell disease, obviously, there's an enormous unmet medical need, and we're seeking to further push forward multiple therapies there for those patients. But, as with any development following any phase of clinical development, there will be go, no-go choices to determine what is the optimal path forward for a particular molecule. In spite of — despite — it produces data for sickle cell disease, but since we're seeking hemolytic anemia and also what we've seen in the top about across varying hemolytic anemias, we are viewing that data as producing optionality for the remaining decision-making across varying indications.

Elizabeth Webster

analyst
#26

This is Elizabeth, filling in for Salveen. With the pivotal trial for PKD in kids scheduled to kick off next year, we were curious to hear your perspective on how finding pediatric patients might look different compared with identifying older individuals. Also, is there anything specific you'd call out on that front?

Sarah Gheuens

executive
#27

Sure. At this point, naturally, our focus for identifying patients centers on whether the clinical trial is feasible; we've followed a quite conventional path in working with sites to learn the number of patients they have and how many would meet the eligibility requirements for the pediatric clinical trials. That's the stage our pediatric plan is in right now. We're really eager to get those studies started during 2022.

Darrin Miles

executive
#28

Also, perhaps the work we currently have underway to help with identifying or profiling patients within the community only covers adults, correct? So pediatric patients are also being encountered by us as we work with the individual practices. And as a result, we're keeping some kind of inventory of that while gathering additional market information.

Andrew Berens

analyst
#29

Two things from me. First, I'd like some clarity on how you intend to handle the $1.2 billion still earmarked for buybacks. Roughly two-thirds has already been spent, and your prepared remarks suggested there's some wiggle room with the last third. Could that portion go toward external BD instead? Or is the commitment to repurchasing stock firm? If it is firm, give us a sense of the schedule. Should the pace resemble what we saw across the past 12 months? Second, a quick thought on 946. Given that it will be tested in sickle cell, do you still intend to move mitapivat forward in sickle cell disease, and if 946 turns out to be the lead candidate there, how far behind would it be?

Jonathan Biller

executive
#30

All right. Jonathan here, and I'll take the buyback question first. Given the headway we've made on repurchases to this point — a bit more than 16 million shares bought back, which has cut our starting share count by slightly over 23% — and having spotted chances within our internal programs to possibly speed them up, plus watching the external BD environment where valuations have fallen quite a bit over the course of this year, we concluded there might be a greater chance of locating workable complementary BD deals. So we've halted share repurchases, which preserves that optionality for us. A 10b-18 plan remains in effect, meaning buybacks are still possible. At present, though, our capital allocation priority for that leftover 2/3 would be chances to accelerate the pipeline, along with doing some — the remaining 1/3, pardon me, 1/3 of the buyback, the $400 million. That's the situation today. No fixed timeline exists for whether or when we might buy back more shares; it'll come down to weighing internal opportunities against possible BD ones. As that unfolds, we'll decide how much, if any, of the additional authorization to use.

Sarah Gheuens

executive
#31

Now, regarding what you asked most recently about how mitapivat is being developed for sickle cell disease, we're really thrilled to keep moving it forward. We discuss it via the appropriate clinical development

Jacqualyn Fouse

executive
#32

Andy, this is Jackie. No one has posed a question to me yet. Right, so I'm starting to feel — well, not exactly ignored. Therefore, I'll chime in; thanks for submitting those 2 questions. I'd also like to highlight that following our completion of the oncology divestiture with Servier, and after we received those proceeds at the end of March, we remained adaptable regarding how we'd approach our capital allocation strategy. Yet what we recognized back then was that we faced a distinctive set of circumstances, considering our position in the Agios life cycle and having carried out what was a fairly sizable transaction for an organization of our scale; and considering the volume of capital we'd accumulated throughout our history, our earliest goal, and that is where the $1.2 million share authorization came from, was to essentially what I'd describe as restructure our capital base by returning a portion of it to our shareholders, something we've now completed, and I believe we're quite pleased with how we've executed on that approximately $800 million or so during the past 6 months. Consequently, we still hold that extra $400 million of authorization. Meanwhile, our teams have achieved considerable headway with certain internal programs throughout 2021, and at present we're seeing some possibilities that we'll discuss on November 17 to make additional investments in our internal assets and programs to push certain things forward, since we now possess the evidence backing the rationale for pushing them forward and advancing them and incorporating those investments into our plan that weren't necessarily present previously. And then, as Jonathan mentioned, we also have improved clarity regarding our internal thinking, I'd say, concerning the possible opportunity set within the BD space. Thus, there are various methods, as you're aware, for deploying your capital across time. And we will always alternate among those in differing ways. However, for the near term, we aimed to make an unambiguous statement regarding the share count reduction through the return of capital, and at this point we'll simply be somewhat more adaptable concerning how we evaluate those various opportunities; and then the final point I wished to make concerns 946, I can recall this from a year or perhaps even longer ago, we understood, as Sarah mentioned, that we intended to produce some data in given hemolytic anemia. And back when we were proceeding with the healthy volunteer study, sickle cell disease appeared to be the most sensible one to include in that protocol to obtain some early data in a given hemolytic anemia disease; and I believe you'll hear on November 17 some additional concepts we have for AG-946, and I'll stop there. Thanks for your questions.

Andrew Berens

analyst
#33

Nice, and I just want to ask a quick follow-up there, Jackie — what's the current headcount on your BD side?

Jacqualyn Fouse

executive
#34

Honestly, that really hinges on your perspective. There are 2 or 3 people whose sole focus is that, yet beyond them, we also have leaders sitting inside each functional group who pitch in on these efforts whenever we're evaluating something. That means you'd find an individual within Bruce's organization helping with asset review, and someone within Sarah's organization who also adds to it < > and naturally, Bruce's group keeps coming up with concepts around complementary mechanisms or targets that are worth our attention — plus we have a compact BD operation, small yet formidable, actively surveying the landscape out there.

Andrew Berens

analyst
#35

All right. Then regarding 946, suppose you were to shift focus to sickle cell and 946 — how much of a gap do you figure separates you from mitapivat?

Jacqualyn Fouse

executive
#36

Let me clarify something: a pivot toward 946 isn't something we expect to make. Our pace with mitapivat is rapid and intense. It's possible that 946 and sickle cell, one day, become complementary pieces within the portfolio; equally possible is that data we obtain for 946 in sickle cell disease reveal something regarding how this product behaves in a particular hemolytic anemia, after which we also have the healthy volunteer data. And beyond that, perhaps additional indications exist into which we'd be comfortable advancing at an even quicker rate, given everything observed across the PKR activator class and the full body of work we've completed, and 946 in particular.

Danielle Brill

analyst
#37

A few questions about the sickle cell and thalassemia studies. I realize you aren't taking patients currently on voxelotor or < >, but will individuals who previously received those agents be allowed to join. And in the same way, for ENERGIZE, will those who have already been given luspatercept be able to enroll.

Sarah Gheuens

executive
#38

Yes and yes. Patients who had those earlier treatments are permitted, provided there's an adequate washout before they enter our trial. That also holds for the thalassemia studies, where earlier luspatercept use is permitted. As I said before, in the sickle cell disease trial, hydroxyurea may be taken alongside as a concomitant medication.

Danielle Brill

analyst
#39

One short additional question. Clearly, your mechanism differs, yet do any requirements exist regarding whether those individuals needed to have responded to earlier therapies?

Sarah Gheuens

executive
#40

No, none exist.

Jacqualyn Fouse

executive
#41

Thanks, operator, and thanks to all of you for your questions this morning. There's a lot to be excited about as we head into the future, starting with the PDUFA date of February 17, 2022 for mitapivat in PK deficiency here in the U.S. We're also awaiting the continuing MAA review for that same indication in Europe, along with the launch of 3 pivotal studies before the year ends covering thalassemia and sickle cell disease in adults, the start of a pediatric PK deficiency clinical program during 2022, an Investor Day scheduled for November 17, and numerous data presentations on the way at ASH. As you can tell, plenty is happening. As I always do, I want to express gratitude to my Agios colleagues for the commitment and enthusiasm they bring to improving patients' lives. My thanks also go out to every patient, caregiver, and physician who works alongside us in so many ways, particularly those enrolled in our mitapivat clinical trials spanning multiple indications. Thanks once more for being with us today. You can disconnect now. Talk to you soon.

Operator

operator
#42

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.